Genetic impairment of frontocortical endocannabinoid degradation and high alcohol preference

被引:120
作者
Hansson, Anita C.
Bermudez-Silvaz, Francisco J.
Hyytia, Petri
Sanchez-Vera, Irene
Rimondini, Roberto
de Fonseca, Fernando Rodriguez
Kunos, George
Sommer, Wolfgang H.
Heilig, Markus
机构
[1] NIAAA, Lab Clin & Translat Studies, NIH, Bethesda, MD 20892 USA
[2] Fdn IMABIS, Malaga, Spain
[3] Natl Publ Hlth Inst, SF-00140 Helsinki, Finland
[4] Univ Bologna, Dept Pharmacol, I-40126 Bologna, Italy
[5] Karolinska Inst, Dept Clin Neurosci, S-10401 Stockholm, Sweden
[6] NIAAA, Neuroendocrinol Lab, Bethesda, MD USA
关键词
endocannabinoids; CB1; SR141716A; FAAH; alcoholism; prefrontal cortex;
D O I
10.1038/sj.npp.1301034
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Endocannabinoid signaling has recently been implicated in ethanol-seeking behavior. We analyzed the expression of endocannabinoid-related genes in key brain regions of reward and dependence, and compared them between the alcohol-preferring AA (Alko Alcohol) and nonpreferring ANA (Alko Non-Alcohol) rat lines. A decreased expression of fatty acid amidohydrolase (FAAH), the main endocannabinoid-degrading enzyme, was found in prefrontal cortex (PFC) of AA rats, and was accompanied by decreased enzyme activity in this region. Binding of the endocannabinoid-cannabinoid 1 (CB1) receptor ligand (3)[H]SR141716A, and [35S]GTP gamma S incorporation stimulated by the CB1 agonist WIN 55,2 12-2 were downregulated in the same area. Together, this suggests an overactive endocannabinoid transmission in the PFC of AA animals, and a compensatory downregulation of CB1 signaling. The functional role of impaired FAAH function for alcohol self-administration was validated in two independent ways. The CB1 antagonist SR141716A potently and dose-dependently suppressed self-administration in AA rats when given systemically, or locally into the PFC, but not in the striatum. Conversely, intra-PFC injections of the competitive FAAH inhibitor URB597 increased ethanol self-administration in nonselected Wistar rats. These results show for the first time that impaired FAAH function may confer a phenotype of high voluntary alcohol intake, and point to a FAAH both as a potential susceptibility factor and a therapeutic target.
引用
收藏
页码:117 / 126
页数:10
相关论文
共 58 条
[1]   A cluster of differentially expressed signal transduction genes identified by microarray analysis in a rat genetic model of alcoholism [J].
Arlinde, C ;
Sommer, W ;
Bjork, K ;
Reimers, M ;
Hyytiä, P ;
Kiianmaa, K ;
Heilig, M .
PHARMACOGENOMICS JOURNAL, 2004, 4 (03) :208-218
[2]   Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors [J].
Arnone, M ;
Maruani, J ;
Chaperon, F ;
Thiebot, MH ;
Poncelet, M ;
Soubrie, P ;
LeFur, G .
PSYCHOPHARMACOLOGY, 1997, 132 (01) :104-106
[3]   Direct and indirect interactions between cannabinoid CB1 receptor and group II metabotropic glutamate receptor signalling in layer V pyramidal neurons from the rat prefrontal cortex [J].
Barbara, JG ;
Auclair, N ;
Roisin, MP ;
Otani, S ;
Valjent, E ;
Caboche, J ;
Soubrie, P ;
Crepel, F .
EUROPEAN JOURNAL OF NEUROSCIENCE, 2003, 17 (05) :981-990
[4]   Role of the endocannabinoid system in the development of tolerance to alcohol [J].
Basavarajappa, BS ;
Hungund, BL .
ALCOHOL AND ALCOHOLISM, 2005, 40 (01) :15-24
[5]   Neuromodulatory role of the endocannabinoid signaling system in alcoholism: an overview [J].
Basavarajappa, BS ;
Hungund, BL .
PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, 2002, 66 (2-3) :287-299
[6]  
CABERLOTTO L, 2003, NEUROPSYCHOPHARMACOL, V25, P1564
[7]  
Carr DB, 1998, SYNAPSE, V29, P193
[8]   Reduced cellular expression and activity of the P129T mutant of human fatty acid amide hydrolase: evidence for a link between defects in the endocannabinoid system and problem drug use [J].
Chiang, KP ;
Gerber, AL ;
Sipe, JC ;
Cravatt, BF .
HUMAN MOLECULAR GENETICS, 2004, 13 (18) :2113-2119
[9]   NEUROGENETIC ADAPTIVE-MECHANISMS IN ALCOHOLISM [J].
CLONINGER, CR .
SCIENCE, 1987, 236 (4800) :410-416
[10]   Appetite suppression and weight loss after the cannabinoid antagonist SR141716 [J].
Colombo, G ;
Agabio, R ;
Diaz, G ;
Lobina, C ;
Reali, R ;
Gessa, GL .
LIFE SCIENCES, 1998, 63 (08) :PL113-PL117